A groundbreaking collaboration has been initiated by Lightstone Ventures, ClavystBio, Leaps by Bayer, Polaris Partners, the Polaris Innovation Fund, and global life science company Evotec SE to establish 65LAB in Singapore. This initiative represents the first-of-its-kind partnership in Singapore, conceived by Lightstone Ventures and Evotec, aimed at harnessing the collective capabilities of these partners to identify and expedite the commercialization of promising research from esteemed academic and research institutions in Singapore, including A*STAR, National University of Singapore (NUS), and Duke-NUS Medical School.

65LAB's objective is to merge Evotec's comprehensive end-to-end R&D platform with Singapore's world-class academic and translational scientific expertise, as well as its burgeoning biotech infrastructure. The collaboration targets the creation of breakthrough therapies with global health impacts.

This unique partnership is a testament to the spirit of collaboration between academia and industry, facilitating the translation of intellectual property into real-world applications. It provides researchers in partner institutions with access to Evotec's Expert-in-Residence, along with direct entry to the company's drug discovery and development capabilities across various therapeutic modalities. 65LAB will invest up to US$1.5 million in each selected academic project over 18-24 months.

The driving force behind this collaboration is the shared vision of fostering company growth and nurturing Singapore's biotech ecosystem. The selected projects will undergo evaluation by 65LAB's board of global investors for further investment and the potential creation of new companies.

65LAB's Board of Directors comprises experienced biotech investors, including representatives from ClavystBio, Lightstone Ventures, Leaps by Bayer, and Polaris Partners, who will oversee the collaboration's strategy and operations.

This innovative partnership exemplifies the industry's commitment to advancing scientific discoveries into impactful therapeutic solutions. It underscores the potential for cross-sector collaboration to address global healthcare challenges and promote scientific innovation.

As Singapore continues to strengthen its position in the global life sciences landscape, 65LAB serves as a pioneering model for translating groundbreaking research into real-world applications, ultimately benefitting patients worldwide. The initiative brings together the best of academia and industry, creating a robust ecosystem for biotech innovation and commercialization.